Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Jan 31

PMID 22286199

Citations 154

Authors

Roland B Walter

Frederick R Appelbaum

Elihu H Estey

Irwin D Bernstein

Affiliations

Soon will be listed here.

Abstract

Although the identification of cancer stem cells as therapeutic targets is now actively being pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia (AML) are a paradigm of such a strategy. Heterogeneity of these cells was suggested by clonal analyses indicating the existence of both leukemias resulting from transformed multipotent CD33(-) stem cells as well others arising from, or predominantly involving, committed CD33(+) myeloid precursors. The latter leukemias, which may be associated with an intrinsically better prognosis, offer a particularly attractive target for stem cell-directed therapies. Targeting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an approach. Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute promyelocytic leukemia but, in combination with conventional chemotherapy, also for other favorable- and intermediate-risk AMLs, providing the first proof-of-principle evidence for the validity of this strategy. Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and failure in various AML subsets.

Citing Articles

Norchelerythrine from (Thunb.) Pers. promotes differentiation and apoptosis by activating DNA damage response in acute myeloid leukemia.

Lee J, Jeon B, Kwon C, Kim H, Kim T, Seo Y Int J Oncol. 2025; 66(3).

PMID: 39918000 PMC: 11837901. DOI: 10.3892/ijo.2025.5723.

Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review.

Liu X, Xu Z, Li S, Zhang X, Li J, Li H Front Immunol. 2024; 15:1461908.

PMID: 39469704 PMC: 11513260. DOI: 10.3389/fimmu.2024.1461908.

CD37 in acute myeloid leukemia: a novel surface target for drug delivery.

Jeremy E, Artiga E, Elgamal S, Cheney C, Eicher D, Zalponik K Blood Adv. 2024; 9(1):1-14.

PMID: 39348689 PMC: 11732606. DOI: 10.1182/bloodadvances.2024013590.

Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.

Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F Leukemia. 2024; 38(12):2598-2613.

PMID: 39294295 PMC: 11588662. DOI: 10.1038/s41375-024-02409-1.

Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy.

Fiorenza S, Lim S, Laszlo G, Kimble E, Phi T, Lunn-Halbert M Mol Ther Oncol. 2024; 32(3):200854.

PMID: 39224504 PMC: 11367471. DOI: 10.1016/j.omton.2024.200854.

References

Robertson M, Soiffer R, Freedman A, Rabinowe S, Anderson K, Ervin T . Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992; 79(9):2229-36. View

Vassiliou G, Cooper J, Rad R, Li J, Rice S, Uren A . Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011; 43(5):470-5. PMC: 3084174. DOI: 10.1038/ng.796. View

Wang Y, Zhou G, Yin T, Chen B, Shi J, Liang W . AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005; 102(4):1104-9. PMC: 545849. DOI: 10.1073/pnas.0408831102. View

Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T . Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996; 87(11):4789-96. View

Gale R, Wheadon H, Goldstone A, Burnett A, Linch D . Frequency of clonal remission in acute myeloid leukaemia. Lancet. 1993; 341(8838):138-42. DOI: 10.1016/0140-6736(93)90004-z. View

van der Jagt R, Badger C, Appelbaum F, Press O, Matthews D, Eary J . Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 1992; 52(1):89-94. View

Nanri T, Uike N, Kawakita T, Iwanaga E, Mitsuya H, Asou N . A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation. Genes Chromosomes Cancer. 2009; 49(3):237-41. DOI: 10.1002/gcc.20734. View

Zdzienicka M, Sankaranarayanan K, Van Buul P . Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin. Mutat Res. 2000; 471(1-2):95-105. DOI: 10.1016/s1383-5718(00)00122-4. View

Goemans B, Zwaan C, Vijverberg S, Loonen A, Creutzig U, Hahlen K . Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia. 2008; 22(12):2284-5. DOI: 10.1038/leu.2008.147. View

10.

Lo-Coco F, Cimino G, Breccia M, Noguera N, Diverio D, Finolezzi E . Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004; 104(7):1995-9. DOI: 10.1182/blood-2004-04-1550. View

11.

Taussig D, Miraki-Moud F, Anjos-Afonso F, Pearce D, Allen K, Ridler C . Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008; 112(3):568-75. DOI: 10.1182/blood-2007-10-118331. View

12.

Scheinberg D, Lovett D, Divgi C, Graham M, Berman E, Pentlow K . A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991; 9(3):478-90. DOI: 10.1200/JCO.1991.9.3.478. View

13.

Muller A, Duque J, Shizuru J, Lubbert M . Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene. 2008; 27(44):5759-73. DOI: 10.1038/onc.2008.196. View

14.

Caron P, Jurcic J, Scott A, Finn R, Divgi C, Graham M . A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994; 83(7):1760-8. View

15.

Huntly B, Shigematsu H, Deguchi K, Lee B, Mizuno S, Duclos N . MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015. View

16.

Lo Coco F, Ammatuna E, Noguera N . Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol. 2006; 4(1):57-62, 76-7. View

17.

Lumkul R, Gorin N, Malehorn M, Hoehn G, Zheng R, Baldwin B . Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia. 2002; 16(9):1818-26. DOI: 10.1038/sj.leu.2402632. View

18.

Hamann P, Hinman L, Beyer C, Lindh D, Upeslacis J, Flowers D . An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002; 13(1):40-6. DOI: 10.1021/bc0100206. View

19.

Monaco G, Konopleva M, Munsell M, Leysath C, Wang R, Ellen Jackson C . Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells. 2004; 22(2):188-201. DOI: 10.1634/stemcells.22-2-188. View

20.

Walter R, Gooley T, van der Velden V, Loken M, van Dongen J, Flowers D . CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007; 109(10):4168-70. PMC: 1885511. DOI: 10.1182/blood-2006-09-047399. View